+ +where are we going?+ +

3 March 2003:

Positive outcomes from a 7 day trial of Phase 2a, drug AOD9604 trial-Date: 3/3/2003 (36 male volunteers)

http://stocknessmonster.com/news-item?S=MBP&E=ASX&N=201482

"Extract: "The principle of AOD9604, already proven in animal studies, is to mimic the natural fat reducing properties of human growth hormone without producing any effects on blood sugar control or growth.

In the 10 mg dose group, the overall weight loss was 1.0 kg compared to 0.4 kg in the placebo group, and in the 20 older volunteers the weight loss was 0.8 kg compared to a weight gain of 0.1 kg in the placebo group".

Comment: The 10 mg dose group did well: an average of 1 kg weight loss in a week.

If they repeated that for 3 months (12 weeks), then that would be 12 kg or 1.9 stone, a very worthwhile reduction without having to diet. Of course, there is no guarantee this will happen.

Gominer: " This one works on the metabolism which is a fat storage incubator, not on the hunger factor."

________________________________________

For release: 6 November 2003
Phase 2B Clinical Trial commences

"Metabolic is pleased to announce that patient recruitment on its Phase 2b clinical trial of
obesity drug AOD9604 is well under way. We believe this to be the largest clinical trial undertaken by an Australian biotech company.

The trial is being conducted at five clinical trial sites across Adelaide, Melbourne (2 sites), Sydney and Brisbane"

"Trial Design
Three hundred obese but otherwise healthy people will participate in this groundbreaking trial.
The 300 trial subjects will be made up of men and women aged 30 to 65 years with a body mass index (or BMI, being weight in kg divided by the square of height in metres) of 35 or higher.

This number of trial subjects has been chosen to ensure that a statistically significant difference between treatment and placebo groups is possible at the conclusion of the trial for all useful amounts of weight loss (i.e. at or above the amount achieved by
existing weight loss drugs).

Medication will consist of capsules containing a daily dose of AOD9604 or placebo in either 0mg (placebo), 1mg, 5mg, 10mg, 20mg, or 30mg quantities. There will be 50 subjects in each dose group".
______________________
2 June 2004:

Metabolic announces completion of recruitment in
Phase 2b AOD9604 obesity trial
For Release: 2 June 2004

We are pleased to advise that full recruitment has now been achieved for Metabolic’s 300-patient Phase 2b clinical trial on obesity drug AOD9604. Over one third of the patients have now finished treatment.

The last patient is expected to finish treatment in
September 2004, with reportable results of the trial available by late November 2004.
__________________________________

Comment: More than one third finished treatment. Waiting for the end of the trial and results in Nov.

Gerry